On Wednesday, BTIG adjusted its outlook on Zimmer Biomet Holdings Inc (NYSE:ZBH), a medical device company, by lowering its price target to $126 from $134, while maintaining a Buy rating on the stock. The revision follows a series of investor meetings with the company's top executives, including President & CEO Ivan Tornos and CFO and EVP Suketu Upadhyah.
During the meetings, discussions centered on Zimmer Biomet's recent announcement regarding a slowdown in its Enterprise Resource Planning (ERP) system implementation. Investors showed keen interest in understanding the implications of this development on the company's operations and future guidance. The company is expected to address the impact of the ERP slowdown on its full-year 2024 guidance in the upcoming third-quarter earnings call.
BTIG's analysis suggests that despite the ERP challenges, Zimmer Biomet is positioned to build a stable foundation for future growth. The firm anticipates that the company could experience mid-single-digit growth rates, supported by strong market conditions and contributions from new products. This growth is expected to trend towards the higher end of the mid-single digits over time, potentially reaching or exceeding 6%.
In other recent news, Zimmer Biomet Holdings Inc is facing a downward adjustment in earnings forecasts due to anticipated disruptions from its enterprise resource planning (ERP) system.
The company's difficulties with shipping products have led Needham, Truist Securities, Canaccord Genuity, and TD Cowen to maintain a Hold rating while adjusting their price targets. Despite these challenges, Stifel has maintained a Buy rating for Zimmer Biomet.
The issues primarily affect the company's Sports Medicine, Extremities, and Trauma (SET) business segment and are anticipated to negatively impact Zimmer Biomet's revenue for the year 2024 by approximately 1%. This translates to an estimated 2% reduction in revenue growth for the second half of 2024.
Zimmer Biomet has completed a $700 million financial transaction involving the issuance of notes due in 2034 and is set to acquire AI-driven surgical guidance firm OrthoGrid Systems.
InvestingPro Insights
To complement BTIG's analysis of Zimmer Biomet Holdings Inc (NYSE:ZBH), recent data from InvestingPro offers additional context for investors. Despite the lowered price target, ZBH's current market valuation of $21.55 billion suggests room for potential growth, especially considering the InvestingPro Fair Value of $123.98, which aligns closely with BTIG's revised target of $126.
InvestingPro Tips highlight that ZBH is trading near its 52-week low and at a low P/E ratio relative to its near-term earnings growth. This could indicate a potential buying opportunity for value investors, particularly given the company's consistent profitability and dividend history. ZBH has maintained dividend payments for 13 consecutive years, demonstrating financial stability even in the face of operational challenges like the ERP implementation slowdown.
The company's financial metrics support BTIG's outlook on growth potential. With a revenue of $7.52 billion in the last twelve months and a revenue growth of 4.58%, Zimmer Biomet is showing signs of the mid-single-digit growth rates that BTIG anticipates. Moreover, the company's strong gross profit margin of 71.79% and operating income margin of 20.68% indicate efficient operations, which could help buffer against short-term setbacks.
For investors seeking a deeper dive into Zimmer Biomet's prospects, InvestingPro offers 8 additional tips, providing a more comprehensive analysis of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.